Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Vaccines and Antiviral Agents

Replacement of the F and G Proteins of Respiratory Syncytial Virus (RSV) Subgroup A with Those of Subgroup B Generates Chimeric Live Attenuated RSV Subgroup B Vaccine Candidates

S. S. Whitehead, M. G. Hill, C. Y. Firestone, M. St. Claire, W. R. Elkins, B. R. Murphy, P. L. Collins
S. S. Whitehead
Respiratory Viruses Section and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. G. Hill
Respiratory Viruses Section and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Y. Firestone
Respiratory Viruses Section and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. St. Claire
Bioqual, Inc., Rockville, Maryland 20850
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. R. Elkins
Experimental Primate Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. R. Murphy
Respiratory Viruses Section and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. L. Collins
Respiratory Viruses Section and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.73.12.9773-9780.1999
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Insertion of the F and G genes of RSV strain B1 into recombinant strain A2. (A) The G and F genes of RSV B1 (stippled rectangles) were amplified by PCR as a single cassette with oligonucleotide primers designed to create upstream PacI and downstream SphI restriction sites. Following an additional modification described below, this cassette was cloned into the naturally occurring PacI site and the previously introducedSphI site of the parental RSV A2 cDNA plasmid (6). The RSV genes are shown as open rectangles; the GS and GE transcription signals are shown as shaded and solid bars, respectively. (B) In order to stabilize the G gene end signal of the B1 cDNA, the sequence in this region was modified as shown (new): the third nucleotide in each of the last 11 codons of the G ORF was changed without altering the amino acid coding assignment; the termination codon of the G ORF was changed to an alternative termination codon; 4 nucleotides were introduced into the downstream nontranslated region of the G gene between the ORF and the gene end signal; the G gene end signal was made identical to that of the F gene of strain A2 by substituting 2 nucleotides and deleting a nucleotide in the A tract; and the G-F intergenic region was shortened by 47 nucleotides and anMfeI restriction site was introduced. The sequence is divided into triplets at coding nucleotides, with the amino acid assignment shown directly below each codon. Nucleotides which differ from the B1 wt sequence are underlined, and the introducedMfeI restriction site is shown in boldface italics.

  • Fig. 2.
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Kinetics of replication in the upper (A) and lower (B) respiratory tracts of chimpanzees inoculated intranasally and intratracheally with wt control viruses A2 and B1 and chimeric viruses rAB and rABcp248/404/1030. The number of animals in each group (n) is shown. The dose of virus administered intranasally and intratracheally to each group was 5.0 log10 PFU/ml, except for wt RSV A2, which was administered at 4.0 log10 PFU/ml (11). Nasopharyngeal-swab and tracheal-lavage samples were collected on the days shown and titered by plaque assay on HEp-2 cell monolayers. The limit of detection for this assay is 0.7 log10 PFU/ml of sample. The data for wt RSV A2 and wt RSV B1 are from Crowe et al. (11, 12).

Tables

  • Figures
  • Table 1.

    Temperature sensitivity and subgroup identity ofwt rAB chimeric RSV and derivatives containing attenuating mutationsa

    Embedded Image
    • ↵a The A2-derived mutations contained in the various rAB derivatives have been described previously and were derived from two different biologically derived viruses,cpts248/404 (16) and cpts530/1030 (41). The mutations were as follows: the cpgenotype consists of five amino acid substitutions in the N (V267I), F (E218A, T523I), and L (C319Y, H1690Y) proteins, which are employed as a set and confer a non-ts attenuated phenotype (8, 42). Here, because of the replacement of the F gene,cp involves only the changes in N and L. The 248 and 1030 mutations involve amino acid substitution Q831L and Y1321N, respectively, in the L protein, each of which confers the tsand attenuation phenotypes (40, 41). The 404 genotype involves an amino acid substitution in L, D1183E, which is not associated with the ts or attenuation phenotype, and a nucleotide substitution in the GS signal of the M2 gene, with confers the ts and attenuation phenotypes (40). The ΔSH mutation involves deletion of the SH gene, which confers a modest attenuation phenotype in vivo (2).

    • b Shut-off temperature is defined as the lowest restrictive temperature at which a 100-fold or greater reduction of titer is observed. The virus titers at the shut-off temperature are boxed.

    • c Infected cell monolayers were immunostained with either RSV F monoclonal antibody (MAb) 92-11C (subgroup A specific) or 102-10B (subgroup B specific) and scored visually for staining. +, staining; −, nonstaining.

    • d Pinpoint plaque size.

  • Table 2.

    rAB chimeric RSV derivatives are attenuated in cotton rats

    VirusaNo. of ratsMean virus titer (log10PFU/g of tissue)b (Duncan grouping)c in:
    Nasal turbinatesLung
    A2wt 66.48 ± 0.03 (A)6.08 ± 0.06 (A)
    B1 wt 66.43 ± 0.05 (A)6.00 ± 0.05 (A)
    rAB52.62 ± 0.11 (B)2.50 ± 0.27 (B)
    rABΔSH62.38 ± 0.24 (B)2.21 ± 0.40 (B)
    rABcp63.48 ± 0.56 (C)3.45 ± 0.23 (C)
    rABcpΔSH63.83 ± 0.11 (C)4.00 ± 0.06 (C)
    • ↵a Rats were administered 6.0 log10PFU intranasally under light anesthesia on day 0 and sacrificed on day 4.

    • ↵b Virus titer was determined in the nasal turbinate and lung tissues and is shown as mean titer ± standard error.

    • ↵c Mean virus titers were assigned to statistically similar groups (A to C) by Duncan’s multiple range test (α = 0.05). Therefore, the means in each column with different letters are significantly different.

  • Table 3.

    The wt rAB chimeric virus has awt-like phenotype in chimpanzees and can be attenuated by inclusion of mutations derived from RSV subgroup A vaccine candidates

    VirusaNo. of animalsDoseb (log10PFU per site)Mean peak virus titer (log10PFU/ml)Rhinorrhea scorebMean serum neutralizing antibody titerc (reciprocal log2)
    Nasopharyngeal swabTracheal lavagePeakMeanDay 0Day 28
    wt RSV B14d 4.02.98 ± 0.261.37 ± 0.673.02.5<3.312.8
    wt RSV B12d 5.02.75 ± 0.252.45 ± 1.452.01.5<3.313.0
    rAB45.04.28 ± 0.124.05 ± 0.173.02.5<3.312.3
    rABcp248/404/103035.02.03 ± 0.19<0.7 ± 0.000.00.0<3.310.5
    • ↵a Chimpanzees were inoculated by the intranasal and intratracheal routes with the indicated amount of virus in a 1-ml inoculum per site. Nasopharyngeal-swab samples were collected daily for 12 days, and tracheal-lavage samples were collected on days 2, 5, 6, 8, and 12.

    • ↵b The amount of rhinorrhea was estimated daily and assigned a score (0 to 4) that indicated extent and severity: 0, none; 1, trace; 2, mild; 3, moderate; 4, severe.

    • ↵c Serum RSV-neutralizing antibody titers were determined by a complement-enhanced 60% plaque reduction assay withwt RSV B1 and HEp-2 cell monolayer cultures incubated at 37°C (4). RSV-seronegative chimpanzee serum used as a negative control had a neutralizing antibody titer of <3.3 log2. Seropositive adult human serum used as a positive control had a neutralizing antibody titer of 11.0 log2.

    • ↵d Historic control animals from Crowe et al. (12).

  • Table 4.

    Chimeric virus rABcp248/404/1030 is protective against challenge with rAB in the upper and lower respiratory tracts of chimpanzees

    Immunizing virusaInoculum doseNo. of chimpanzeesMean virus titer following RSV challenge (log10PFU/ml)Peak rhinorrhea scoreb
    Nasopharyngeal swabTracheal lavage
    Day 3Day 5Day 7Day 3Day 5Day 7
    rABcp248/404/10305.02<0.7 ± 0.001.00 ± 0.40<0.7 ± 0.00<0.7 ± 0.00<0.7 ± 0.00<0.7 ± 0.000
    None43.12 ± 0.163.72 ± 0.144.28 ± 0.12<0.7 ± 0.003.78 ± 0.263.80 ± 0.153
    • ↵a Chimpanzees were inoculated by the intranasal and intratracheal routes with the indicated amount of virus in a 1-ml dose per site. After 28 days, the chimpanzees were administered 5.0 log10PFU of rAB by the intranasal and intratracheal routes. Nasopharyngeal-swab and tracheal-lavage samples were then collected after 3, 5, and 7 days.

    • ↵b The amount of rhinorrhea was estimated daily and assigned a score (0 to 4) that indicated extent and severity: 0, none; 1, trace; 2, mild; 3, moderate; 4, severe.

PreviousNext
Back to top
Download PDF
Citation Tools
Replacement of the F and G Proteins of Respiratory Syncytial Virus (RSV) Subgroup A with Those of Subgroup B Generates Chimeric Live Attenuated RSV Subgroup B Vaccine Candidates
S. S. Whitehead, M. G. Hill, C. Y. Firestone, M. St. Claire, W. R. Elkins, B. R. Murphy, P. L. Collins
Journal of Virology Dec 1999, 73 (12) 9773-9780; DOI: 10.1128/JVI.73.12.9773-9780.1999

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Replacement of the F and G Proteins of Respiratory Syncytial Virus (RSV) Subgroup A with Those of Subgroup B Generates Chimeric Live Attenuated RSV Subgroup B Vaccine Candidates
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Replacement of the F and G Proteins of Respiratory Syncytial Virus (RSV) Subgroup A with Those of Subgroup B Generates Chimeric Live Attenuated RSV Subgroup B Vaccine Candidates
S. S. Whitehead, M. G. Hill, C. Y. Firestone, M. St. Claire, W. R. Elkins, B. R. Murphy, P. L. Collins
Journal of Virology Dec 1999, 73 (12) 9773-9780; DOI: 10.1128/JVI.73.12.9773-9780.1999
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

HN Protein
Respiratory Syncytial Virus, Human
Vaccines, Synthetic
Viral Envelope Proteins
Viral Fusion Proteins
Viral Proteins
Viral Vaccines

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514